EWY vs IBB
iShares MSCI South Korea ETF vs iShares Biotechnology ETF
- • IBB has the lower expense ratio at 0.44% vs 0.59% for EWY.
- • EWY pays a higher dividend yield (1.34%).
Side-by-side metrics
| Metric | EWY | IBB |
|---|---|---|
Expense ratio Annual fee. Lower is better. | 0.59% | 0.44% |
Dividend yield Trailing 12-month yield. | 1.34% | 0.16% |
AUM Assets under management — bigger funds are typically more liquid. | $22.30B | $11.50B |
YTD return | 46.16% | 30.22% |
1-year return | — | — |
3-year return Annualized. | — | — |
5-year return Annualized. | — | — |
10-year return Annualized. | — | — |
Beta (3Y) Volatility relative to the market. Closer to 1 = market-like. | 2.62 | 0.60 |
P/E ratio | 10.17 | 25.48 |
Last price | $149.42 | $217.75 |
Inception | — | — |
Issuer | iShares | iShares |
EWY top holdings
| 000660.KQ | SK hynix Inc | 23.76% |
| 005930.KQ | Samsung Electronics Co Ltd | 23.03% |
| 402340.KQ | SK Square | 2.96% |
| 009150.KQ | Samsung Electro-Mechanics Co Ltd | 2.61% |
| 105560.KQ | KB Financial Group Inc | 2.13% |
| 055550.KQ | Shinhan Financial Group Co Ltd | 1.57% |
| 006400.KQ | Samsung SDI Co Ltd | 1.45% |
| 086790.KQ | Hana Financial Group Inc | 1.45% |
| 005380.KQ | Hyundai Motor Co | 1.44% |
| 068270.KS | Celltrion Inc | 1.35% |
IBB top holdings
| GILD | Gilead Sciences Inc | 8.94% |
| AMGN | Amgen Inc | 8.31% |
| VRTX | Vertex Pharmaceuticals Inc | 7.87% |
| REGN | Regeneron Pharmaceuticals Inc | 6.24% |
| MRNA | Moderna Inc | 5.49% |
| NTRA | Natera Inc | 3.78% |
| ARGX | argenx SE ADR | 3.36% |
| BIIB | Biogen Inc | 2.52% |
| RVMD | Revolution Medicines Inc Ordinary Shares | 2.50% |
| ILMN | Illumina Inc | 2.41% |
About EWY
EWY (iShares MSCI South Korea ETF) is South Korean large and mid-cap equities. Managed by iShares, the fund carries $22.3B in assets under management, an expense ratio of 0.59%, a dividend yield of 1.34%. Its largest holding is SK hynix Inc (000660.KQ), which represents 23.8% of the portfolio. Consumer Cyclical is the fund's largest sector exposure at 4.6%.
About IBB
IBB (iShares Biotechnology ETF) is NASDAQ biotech and pharmaceutical companies. Managed by iShares, the fund carries $11.5B in assets under management, an expense ratio of 0.44%, a dividend yield of 0.16%. Its largest holding is Gilead Sciences Inc (GILD), which represents 8.9% of the portfolio. Healthcare is the fund's largest sector exposure at 100.0%.